Treatment and management of rheumatoid arthritis

At present there is no cure for rheumatoid arthritis. The Australian Models of Care for the management of the disease focus on early diagnosis, early management, and coordination of multidisciplinary care needs (Speeran et al. 2014; Arthritis Australia 2014). The goal of rheumatoid arthritis treatment is to stop inflammation (put the disease in remission), relieve symptoms, prevent joint and organ damage, reduce complications and improve physical function. Early treatment for rheumatoid arthritis is aggressive in order to stop inflammation as soon as possible (Arthritis Australia 2014).

Medications are primarily used to treat rheumatoid arthritis, however physical therapy and surgery can also be used.


Treatment for rheumatoid arthritis has improved dramatically over the past 20 years, with new medicines now very helpful for people, particularly in the early stages of the disease.

Medications for symptoms

Simple analgesics (such as paracetamol) may be used for pain management. Based on the patient’s needs, doctors may also prescribe other medications to manage pain and/or stiffness, such as fatty acid supplements, nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors and low dose corticosteroids (RACGP 2009).

Medications for slowing disease

Disease-modifying anti-rheumatic drugs (DMARDs), biologic disease-modifying anti-rheumatic drugs (bDMARDs), and corticosteroids may slow disease progression (Nam et al. 2014, RACGP 2009). Corticosteroids and DMARDs are typically prescribed and monitored by specialist rheumatologists and require close medical monitoring to ensure effectiveness and to minimise side effects (RACGP 2009). Evidence suggests initiation of aggressive treatment with DMARDs within 12 weeks of symptom onset is associated with less joint destruction and a higher chance of achieving DMARD-free remission as compared with a longer delay in assessment (Van der Linden 2010).

bDMARDs are specialised immunosuppressant medications that have been shown to halt or slow the disease process sufficiently to reduce the joint destruction and disability associated with early rheumatoid arthritis (Nam et al. 2014). bDMARDs are also used for other autoimmune conditions such as juvenile arthritis, psoriatic arthritis and Crohn's disease.

Treatment options for rheumatoid arthritis, including bDMARDs are available through the Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS) (AIHW 2013).

Physical therapy

Maintaining a healthy and active lifestyle is an important management strategy in rheumatoid arthritis. Low-impact physical activity can assist in reducing inflammation, increasing and maintaining mobility and strengthening muscles around affected joints (Cooney 2011).  A physiotherapist can prescribe an exercise program to assist in the management of rheumatoid arthritis. 

Joint replacement surgery

Joint replacement surgery can relieve pain and restore function to joints severely damaged due to rheumatoid arthritis.

General practitioners and rheumatoid arthritis treatment

Treatment of rheumatoid arthritis often begins with the patient visiting a general practitioner (GPs). This is an important step in the treatment of rheumatoid arthritis because it is optimal for inflammation to be managed early on to reduce the chances of joint damage occurring (Speerin et al. 2014) and improve long-term outcomes (Bakker et al. 2011). GPs often conduct initial assessment and diagnosis of rheumatoid arthritis. The time from onset of rheumatoid arthritis symptoms and referral to a specialised rheumatologist for treatment needs to be as efficient as possible to improve long-term treatment outcomes (Nam et al. 2014). The RACGP recommends GPs complete diagnosis of rheumatoid arthritis as soon as possible and refer patients to a rheumatologist if joint swelling persists beyond 6 weeks (RACGP 2009).

Hospitalisation and the treatment of rheumatoid arthritis

Treatment of rheumatoid arthritis is usually managed by general practitioners in partnership with rheumatologists and allied health professionals (such as physiotherapists) and centres on managing pain, reducing inflammation and joint damage, and preventing loss of function.

Severe disease however may require hospitalisation to relieve pain and restore function to damaged joints.

Data from the AIHW National Hospital Morbidity Database (NHMD) show that, in 2017–18:

  • there were 12,045 hospitalisations with the principal diagnosis of rheumatoid arthritis, a rate of 43 hospitalisations per 100,000 population (age standardised to the 2001 Australian population)
  • three-quarters (75%) of rheumatoid arthritis hospitalisations were for females
  • the hospitalisation rate was lowest among those aged 40 and under, increased until the age of 70–74, and then decreased again among people aged 75 and over (Figure 1).

Figure 1: Rate of hospitalisation for rheumatoid arthritis, by sex and age, 2017–18

This vertical bar chart compares the rate (per 100,000 population) of hospitalisations for rheumatoid arthritis, across various age groups by sex, in 2017–18. The rate of hospitalisations was highest in the 70–74 age group for both males (102) and females (251), and lowest in the <40 age group for both males (3) and females (13).

Source: AIHW National Hospital Morbidity Database (Data table).

Between 2008–09 and 2017–18, the age-standardised hospitalisation rate for rheumatoid arthritis peaked in 2015–16 at 50 per 100,000, compared with 43 per 100,000 in 2017–18. The hospitalisation rate peaked at 73 per 100,000 for females and at 26 per 100,000 for males, in 2015–16 (Figure 2).

Figure 2: Rate of hospitalisation for rheumatoid arthritis, by sex, 2008–09 to 2017–18

The line chart shows that between 2008–09 and 2017–18, hospitalisation rates (per 100,000 population) for rheumatoid arthritis peaked for both males and females in 2015–16. After adjusting for age, the rate of hospitalisations for rheumatoid arthritis for males peaked at 26 per 100,000 in 2015–16, and was down to 22 per 100,000 in 2017–18. The rate for females peaked at 73 per 100,000 in 2015–16, down to 64 per 100,000 in 2017–18.

Note: Rates are age-standardised to the Australian population as at 30 June 2001.

Source: AIHW National Hospital Morbidity Database (Data table).

Common hospital procedures for rheumatoid arthritis

In 2017–18, a total of 20,807 procedures were performed in rheumatoid arthritis hospitalisations. Administration of pharmacotherapy (40%), generalised allied health interventions (including physiotherapy, occupational therapy and dietetics) (25%) and cerebral anaesthesia (5.9%) were the most common groups (blocks) of procedures for rheumatoid arthritis hospitalisations.

For more information on the treatment and management of rheumatoid arthritis, see the Australian Rheumatology Association and Arthritis Australia